A 3-months Randomized, Placebo-controlled, Parallel Group, Double-blinded, Multi-centre, Phase I Study to Assess Tolerability and Safety of AADvac1 Applied to Patients With Mild-Moderate Alzheimer's Disease With 3-months Open Label Extension
Latest Information Update: 07 Nov 2021
Price :
$35 *
At a glance
- Drugs AADvac 1 (Primary) ; Aluminium hydroxide
- Indications Alzheimer's disease
- Focus Adverse reactions; First in man
- Sponsors Axon Neuroscience
- 10 Dec 2016 Results published in the AXON Neuroscience Media Release.
- 18 Mar 2016 Results published in AXON Neuroscience media release.
- 11 Nov 2015 According to an AXON Neuroscience media release, the results of this study were presented at the 8th International Conference on Clinical Trials in Alzheimers Disease (CTAD) 2015.